Cipla has reported results for first quarter ended June 30, 2012.
On standalone basis, the company has reported a surge of 58.19% in its net profit at Rs 400.76 crore for the quarter, as compared to Rs 253.34 crore for the same quarter in the previous year. Total income of the company has increased by 23.85% to Rs 2011.25 crore for the quarter under review as compared to Rs 1623.98 crore for the quarter ended June 30, 2011.
Cipla manufactures drugs to treat cardiovascular disease, arthritis, diabetes, weight control, depression and many other health conditions. Its products are distributed in more than 180 countries worldwide. The Mumbai-based firm which enjoys the highest share in India's pharmaceuticals market is known for selling low-cost generic versions of anti-retroviral drugs used to fight HIV/AIDS.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: